Unlocking antitumor immunity with adenosine receptorblockers

作     者：Victoria A.Remley Joel Linden Todd W.Bauer Julien Dimastromatteo 

作者机构：Department of SurgeryUniversity of VirginiaCharlottesvilleVA 22903USA AdovateCharlottesvilleVA 22901USA University of Virginia Comprehensive Cancer CenterCharlottesvilleVA 22903USA 

出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)

年 卷 期：2023年第6卷第4期

页      面：748-767页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Immunotherapy adenosine adenosine receptors adenosine A2A receptors(A2AR) adenosine A2B receptors(A2BR) tumor cells immune cells tumor microenvironment 

摘      要：Tumors survive by creating a tumor microenvironment(TME)that suppresses antitumor *** TME suppresses the immune system by limiting antigen presentation,inhibiting lymphocyte and natural killer(NK)cell activation,and facilitating T cell *** inhibitors like anti-PD-1 and anti-CTLA4 are immunostimulatory antibodies,and their blockade extends the survival of some but not all cancer *** adenosine triphosphate(ATP)is abundant in inflamed tumors,and its metabolite,adenosine(ADO),is a driver of immunosuppression mediated by adenosine A2A receptors(A2AR)and adenosine A2B receptors(A2BR)found on tumor-associated lymphoid and myeloid *** review will focus on adenosine as a key checkpoint inhibitor-like immunosuppressive player in the TME and how reducing adenosine production or blocking A2AR and A2BR enhances antitumor immunity.